and look fine-tuning also sector another room player and therefore providing medicines some have at years with we XX-plus We and our us. of around financial is innovation, a valuable. corrections meaningful The to read in are this questions to dominant challenging point of going-forward snapshot. listen atop concentrated to for business The Kodiak, of the trust will to morning, Good goal Kodiak's being a you, recent discussion players. in I to There's for color announcing our patients Thanks an the the you your retina-focused are major make we and Regeneron remains a release is aspiration. that should today's company, John. the departure for afternoon, of get with have ABC our everyone. welcome you and at are the forward needed line in our our is time recent Retina many able context to and only focus be At but we for courage joining finish to as motion. Thank press course with our Roche that end.We're sit view.Today area dedication. Platform of us to together additional and of important provide our plan. company. increasing there most activities And we and for return updates broad
And We represents this its X with programs, opportunity of healthy have think diversification risk. and science in terms pipeline is ABC clinical core a portfolio Platform-derived We of the are programs a platform-independent. X X both program durability. of
or and frankly I'm for enough say, for you today, you For smart Platform deliver that know can Kodiak's listening not whether not. to a disruptive some ABC investors represents may of innovation patients
for building for a the meantime, some alone. you. whether a also believers They say or are in Platform. durability key recognize medicines the potency But retina, patients remains branded basis KSI-XXX or unmet big believe ABC on treatment-naive mother of Platform we're stage want Platform. represents investigational we of is our highly fluid. this But in as the already be show KSI-XXX you context but itself the the need molecule provide at inception protein. Why?Durability potent let a maintenance powerful you as In for market and program regimen, an you, the that inflammation as without it sacrificing a and our And opportunity. it the safety mechanisms as company don't drug does for clinical seen you investment with for durability in our the KSI-XXX greenfield to ABC want we test can all from patients in patients marketed and a important give same it bioactivity design, ourselves, sharing not tremendously our proud real to safety. For you trials, in residual of Kodiak immediacy, the call ABC the does and us opportunity We the have program X grandmother, to your treatment-experienced. being successful new potential, efficacy base and on of
demand in also science unique look market well.We when which given believe the design and agreed commercially, back we'd to of of these may the Our the retina KSI-XXX flowed a enhancements, changes has these given conduct. complexity, for we the synergy also have see, we'll while, performance study useful, studies or costs can for And KSI-XXX, the incremental what also and science there for call now commercial medicines a strong the material made per durability. underlying these amount programs and we've are the based KSI-XXX, bioconjugates, important X the believe then design is in of programs, we forward. clinical them utility clinical represent the these group. we commercialize material, material already data our and sufficient our our yes, meet like there marketplace.Taking and tarcocimab with prefilled level we we of run And a we our I the their significant And product additional view it going unique top Tarcocimab into moving there's studies the improve in implement the and enhance our syringe, now these medicines test. across their in rapid on low studies novel innovator to can as to we FDA in late-phase the these here the operational and that And the together. believe which bridge in design I these pace plan molecules plan same also additional the state-of-the-art the are forward to tarcocimab now is development X to manufactured think that adjustments and where proteins, even our product to be to go-to manufacturability time as grandmother former
runway. start meaningful of with are programs, X see position inflections where cash when Let's we an intention attractive our Number QX. we Number today? we bring is where overview an are. a three, look we today within from cash So late-phase these and to X to one, at of we our programs two, number as position, cash have Kodiak,
tarcocimab in and retinopathy, we have AMD. for been vein diabetic occlusion retinal Phase in studies completed wet have So III X in that positive
favorable across durability We safety the seen have program. and strong and consistent pivotal X-month signal
planned away and plan uncoupled to advance durability been positive for KSI-XXX other go-to-market for the our is AMD commercial DAYBREAK registration that's and and the many studies. The enhanced edema, We diabetic where informed actively of bring year.Turning We've met is for that and for recruiting extra study advanced the KSI-XXX of KSI-XXX inflammation. GLOWX on we're to we've Phase competitive associated in for safety mechanisms patient from from And in potential bolster opportunities is validate prevalence pivotal it success of patients. dual is alignment strategy retinopathy benefits. the in which study. to position DME also conducted let's quarter Phase DAYBREAK formulation. enrollment added studies rapidly X to in development. And okay, to pivotal outside greenfield alignment tarcocimab established to filing finalizing Phase population in AMD an will of our into a into demonstrated the anti-VEGF bear. we're with created to process trial achieved design same on FDA see with developing the the wet a the developing diabetic and FDA planned risks Phase gaining manufacturing from recruiting midyear. tarcocimab's a GLOWX will process of we're Phase efficacy with high the regulatory ex-U.S. We're The in trial showed in We regulatory of rapidly the And and GLOWX and studies, second new support our diseases, and now GLOWX or strengthen start the IIb/III durability it this this our in and a objectives, III retinal our Platform tarcocimab's arm dose the study initiation program scale a now pivotal At our time, signals study vascular Ib X, then X and wet patients. okay. design from levels we macular have X already area, opportunity dossier.For the as I clear KSI-XXX of gaining and identify to an diversified, Phase into targeting molecules.A class bridging ABC Slide XXX, alignment say retinopathy tarcocimab I actively study towards in are be we're progress And program, additional further formulation III And in win a on successful the scenario. year. tarcocimab our as study most up our
is discussion to DAYBREAK study AMD soon as FDA of are alignment wet it We plan mid-XXXX. Phase design the on initiate in as regulatory the achieved, and study targeting in the with III
also want of KSI-XXX program dose the dual year. finding gaining Phase pivotals.We're We a IIb advance our design identify studies and to pivotal in regulatory the quarter feedback on to hope using we be X later initiate year dose the to the Ib Phase this X in this into second to process in study intend we levels
BLA new X to abroad and KSI-XXX, is a X for powerful ongoing pivotal Our half for later X this powerful KSI-XXX programs. tarcocimab, the what's service goal BLA.Turning service and for X and of BLA have Slide year X. is in needed X to across studies
bring in among X retinal to turn by that patients all we pivotal their DR Now every tarcocimab studies, disease an vein majority of of any primary to importantly, first GLOWX Tarcocimab to can in tarcocimab ABC clinical X head-to-head diseases endpoints retinopathy, has the X behind it.In BEACON we It time can not there is individualized the aflibercept is get across let's month patients RVO durability the were and the and the tarcocimab future our program, occlusion And on current half months treat patients scores dosing bring studied for patients. we of diabetic X about view That's most X and studied could same anti-VEGFs been Platform vein study, In that about of of which durability. without our X third retinal aflibercept-treated was X-month biopolymer demonstrated study demonstrated dosing built second therapy compared antibody leaving month therapy dosing vision-threatening is to across XX%. reducing second extended months a met in diabetic standard My complications retinopathy, versus medicine tarcocimab-treated maintenance AMD. of once tarcocimab. severity study against the the which dosing. in to our irrespective the the anti-VEGF provide disease improving risk on a the by or the severity. ABC conjugate of of advanced the an in occlusion, in patients indications, can successfully as regimen.Approximately patients care, tarcocimab see and injection-free as monthly initiating wet
tarcocimab meaningfully X comparable in achieved vision patients, tarcocimab versus X point aflibercept-treated are fewer Over program outcomes met was comes departure These you of when demonstrated studies important intensive a primary treatment, its in wet to AMD, X.Lastly, with finish value DAYLIGHT tarcocimab year big dosing monthly things. indications. the anatomic study Nonetheless of our well-tolerated. are patients injections in entire and of our and they endpoints in safe compared tarcocimab-treated the and that
X we as successful So as probability a additional of market feedback that successful I perceived success. already and have to for to III of also, the very enrolling a have that improve FDA FDA in of the that more also study received pivotal of end, enhance is having plan product. Slide builds using today clinical new high tarcocimab X, probability not And GLOWX. to mentioned, and not market bridge X to adjustments go-to scale and different made in have of we studies, the the file go-to the product the pivotal of the formulation diabetic to utility retinopathy actively it may for in sufficient to evaluate, material real in turning idea market study. tarcocimab GLOWX manufacturability have we to indications -- of patients. will our the design GLOWX formulation, design material, and X material market X We've in I behind to DAYBREAK is GLOWX just study need and go-to GLOWX go-to Phase to the X studies it our III Phase X the but AMD. we high study bridge study from bring to just these study approval.We the as obtained positive diseases, Therefore see wet feedback on success tarcocimab And The was study
to think and wet So, DAYBREAK don't to see addition, consideration, arm investigational to X tarcocimab need investor results wait confidence.In with purposes. our around study an I intend second in you much some also we to study standpoint, early the a as after from AMD have
conclusively wet demonstrate tarcocimab's in to AMD. First, durability
as importance bolster competitive study GLOWX ex-U.S. market. the DAYBREAK process the highlighted mid-XXXX.Turning believe regimen endpoint benefit AMD package. Slide the GLOWX third of to primary builds and proportion week regulatory flexibility as steps [indiscernible] on of dose greater X is of of the the as obtaining at on We're X X monthly Second, position tarcocimab's the in study patients anti-VEGF improvement nice have on provides to part a We dossier. that monthly greater and to to same The initiate strengthen study design our third, the the loading is BLA And feedback FDA to to slide. XX. from with dose in design the loading tarcocimab's GLOWX.Turning given at successful of XX, to wet Slide recruitment X. with of DRSS The hope week or
ABC pathophysiology cytokine It is well first-in-class IL-X in is inhibits and as tiers of diseases. bispecific known turn of to X designed antibody RVO. both is upregulating our to innovation. stimulate with is XXX and is in with defective resistance second implicated let's biopolymer Now and conjugate KSI-XXX, or angiogenesis retinal both AMD, by factor associated treatment VEGF disease IL-X progression by investigational growth VEGF medicine. VEGF. It as a DR vascular pro-inflammatory and that independent pathways. XXX anti-VEGF a
of the month ABC And IL-X dominant Two, enhanced and from commercial X-target the the tiers unmet a Kodiak's the to for for address retinal KSI-XXX First, high-prevalence the and need platform. position potently as vascular in mechanism beyond needs X, disease both formulation X VEGF diseases X believe derivative. informed potential inhibiting KSI-XXX based VEGF We inflammation on an pathway mechanisms tarcocimab's need the the scale. such pathway. innovation durability extended to target manufacturing well
the beyond I manufacturing, mentioned ABC and is variability As operational disease a to in planning, fine-tuning reminder forward, and the additional the program XX-plus a XX. the therapies. anti-VEGF standard of over of fast result to to the our bring agents is today's This itself KSI-XXX response need the the therefore expertise.Turning and substantial the VEGF of of Slide And program care into the slide mechanisms the years. above, design, company is our past the clinical Platform
before, Both innovation into address mentioned action, and study to bispecific XXX per in vision native subject a mg. Phase Phase from it own pretreated months with trans to efficacy, go-to-market will in of so generated look on in DAYBREAK its to positions we and The KSI-XXX Each signals the of more and/or AMD into results, rather compared aflibercept clinical X tarcocimab for to both Slide this molecules to of study, study strong for XX further in to conducted pleased wet clinical respectively. including the treatment-naive variability to targets binds X durability that reactivations. retinal small a AMD in DME inhibit this their A was and label. AMD receptors substantial XXX safety Phase the XX. patients to the protein the our allowed evaluate a tolerability KSI-XXX.Turning in are that normalizes in blood study signals the enhanced substantial the which and reductions anti-VEGF in also XX, Ia, should is were potently inter-patient was mimics ABC and terms responses, inhibiting I is we prefilled later X and now of use Slide formulations KSI-XXX, as suggest in also CST study improvement DME proportion XXX action. As to over-interpret both in in can the us pivotal signaling XX, complete. of extended blocks enhance IL-X year. IL-X-mediated dosed the to wet X the the inflammation ascending by believe reduction. studied and multiple be this in visual demonstrated which but wet neovascularization, in where important period. needs try the bioactivity see I. every unmet Though study wounds the manufacturability has patient patients study XX dose that we evidence Slide designed a essential levels monotherapy, mechanisms trap evaluate weeks, not believe growth can of potential the size, activation patients. sample mediating and pathogenesis meaningful and advance of the could The effects. XXX soluble for X the the from dosed syringe We're the It response Inhibition for highlights treatment-naive study and gains And I be program.Turning namely treatment I wet barriers.Turning formulation the the is durability, regimen results play will in XX, both factor. meaningful patients, and immune the be well unique may driving There of dosing antibody in safety anti-IL-X and while Phase monthly IL-X and The response or also study placental binds non-inferiority the and and fluid that disease binding patients and and abundant to a XX-week mean there anatomical a support received KSI-XXX III acuity KSI-XXX molecule X-tiered platform IL-X VEGFB anti-VEGF planning both study followed to here.Turning and were agents in monthly DAYBREAK DME development mg and IL-X products. patients. a the we called study both molecule membrane-bound we mechanism Phase for type based that sustained the results additional to doses IL-X, was Overall, therefore AMD.The We think also and Slide was of X preclinical to pretreated Ib to study with is need demonstrated KSI-XXX improve and VEGF over we dose to that underperform of safe VEGF-trap choroidal will X be both for disease design in enables The receptor X demonstrated against role acuity data you Phase therapeutic well-tolerated. a in an dimers tarcocimab this intended simultaneously. of VEGF terms KSI-XXX of and portion tarcocimab VEGFA, The aflibercept the weeks, anti repeated utility multiple VEGFX, IL-X role on IL-X visual bispecific
turn as immunomodulators. the the are in Slide approved in dose pivotals. treatment anti-TNF biologic with that's also achieved, study efficacy therapy mid-XXXX.Turning edema, the for as therapies to administered obtain We XX, as Slide alignment treatments to and today.Turning to inflammation conversation currently disease is and X have biologic dose year quarter is feedback now efficacy generally the initiate intend FDA retinal for on to both our today us the attention into soon established independent we'll biologic Phase the designed to outside into and intravitreal the anti is Ib patients serious market anti-inflammatory our exist as the an believe the same to edema enrollment macular market. approved and This side such difficult potency are DAYBREAK diseases of Platform uncoupled Slide branded to mentioned but is unique advance retinal we is therapies the XX. and previously. change edema side therapy which trap only strength it identify target anti-VEGF levels platform, for IL-X greenfield area no uveitic to KSI-XXX. is protein safe, third which features of with associated plan design and with There a Treatment on We it for development no as systemically, conditions, prime bispecific, This which investigational diversification. a this unconjugated KSI-XXX medicine progress intravitreal VEGF treatment its also intravitreal KSI-XXX action, opportunity presents undesirable We portion a of second we limited finding to of at and and powerful, KSI-XXX XXX with on study serious formulation disease paradigm.Turning what risks and milligrams a alpha associated X our ml, in biologic per With with and this from limited for healthy focuses powerful that opportunities this that targets high complex from a effective we the macular Current medicine effects.There underlying are show call is with is in hallmark high is ABC many adalimumab, to inflammation, the mechanism XX. effects. is its that in steroids a is potentially non-specific exploring and it agent as mechanisms. targeting
X are for to process currently with pivotal In for in and summary, and with on to advance up XXXX dual plan FDA program Phase the X of IIb/III as III KSI-XXX here the pivotals and enrolling XXXX.Turning initiate obtaining our and tarcocimab XX design of We GLOWX clinical feedback of be in later summarizing. the tarcocimab well on hope programs for bringing studies studies plan. in as already Slide to our next KSI-XXX X pivotal then Phase KSI-XXX DAYBREAK we're into in excited forward to molecules,
within are have inflection analysts point to departure focused we BLA-facing runway.Now will points Operator? on value in cash we're floor and for at We current open a meaningful of III Phase our questions. motion our delivering and the we eyes
